The advent of cancer immunotherapy based on PD-1 and CTLA-4 immune checkpoint
blockade (ICB) has revolutionized cancer treatment. However, many cancers do not respond …

CD8+ T cells are the workhorses executing adaptive anti-tumour response, and targets of
various cancer immunotherapies. Latest advances have unearthed the sheer heterogeneity …

Immune cell dysfunction within the tumor microenvironment (TME) undermines the control of
cancer progression. Established tumors contain phenotypically distinct, tumor-specific …

Dendritic cells (DCs) are uniquely capable of transporting tumor antigens to tumor-draining
lymph nodes (tdLNs) and interact with effector T cells in the tumor microenvironment (TME) …

Dendritic cells (DCs) play a pivotal role in immune surveillance, acting as sentinels that
coordinate immune responses within tissues. Although differences in the identity and …

Controlled-release systems enhance anti-tumor effects by leveraging local antigen
persistence for antigen-presenting cells (APCs) recruitment and T cell engagement …

The ability to characterize immune cells and explore the molecular interactions that govern
their functions has never been greater, fueled in recent years by the revolutionary advance …

Simple Summary The last decade has seen dramatic changes in cancer treatment. Various
methods of the immunotherapy of solid tumors, including treatment with targeted monoclonal …

Tertiary lymphoid structures (TLSs) are organized lymphoid aggregates that form within
nonlymphoid tissue, including tumors, in response to persistent inflammatory stimulation. In …

Immune responses require complex, spatially-coordinated interactions between immune
cells and their tissue environment. For decades, we have imaged tissue sections to visualise …